Shanghai Runda Medical Technology Co., Ltd. provided earnings guidance for the nine months ended September 2018. It is predicted that the total business revenue will be between RMB 4.1 billion and RMB 4.5 billion from January to September 2018, with a year-on-year increase of between 40% and 54%. It is predicted that the net profit belonging to the shareholders of the listed companies will be between RMB 235 million and RMB 258 million from January to September 2018, with a year-on-year increase of between 40% and 54%. The net amount of cash flow generated in production activities will be between RMB 160 million and RMB 240 million from January to September 2018, with an obvious improvement compared with net cash used in production activities Of RMB 150.39 million in the same period of the year before.
Shanghai Runda Medical Technology Co Ltd is a China-based company primarily engaged in the research, development, production and sales of medical devices and in vitro diagnostic reagents. The Company operates two businesses. The integrated services business provides a full-industry supply chain service to various medical laboratories, including product portfolio services, cold chain warehousing and logistics, regular instrument maintenance and repair, and localized rapid response repair services, integrated service and regional testing center service, as well as third-party laboratory testing services. The industrial business is primarily engaged in the research, development, production and manufacturing of in vitro diagnostic (IVD) products, as well as the development of digital information systems and software. The Company primarily operates its businesses in the domestic market.
Choose MarketScreener 
